Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ITGB8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGB8 (or ITGAV/ITGB8 Heterodimer) ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View ITGB8 Products |
| Gene Delivery | ITGB8 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based latent TGF-beta activation assays. |
View ITGB8 Products |
| Benchmark Ab | Anti-ITGB8 Recombinant Antibody (Sequence of GSK3810109 / PF-06940467) Recombinant positive control for binding and functional block. |
View ITGB8 Products |
| Validator | ITGB8 siRNA Set For knockdown verification in target-validation assays. |
View ITGB8 Products |
| Related Target A | ITGAV (Integrin alpha-V) Required heterodimerization partner for functional alpha-v/beta-8 complex. |
View ITGAV Products |
| Related Target B | TGFB1 (Transforming Growth Factor Beta 1) Primary downstream effector activated by ITGAV/ITGB8-mediated cleavage. |
View TGFB1 Products |
| Related Target C | PDCD1 (PD-1) Synergistic target; ITGB8 inhibition overcomes resistance to anti-PD-1 therapies. |
View PDCD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Conformational Integrity | Co-expressed ITGAV/ITGB8 stable heterodimer proteins with verified molecular weight and high purity (>95%). |
| Integrin Subfamily Counter-Screening | Cross-reactivity panels including ITGAV/ITGB1, ITGAV/ITGB3, ITGAV/ITGB5, and ITGAV/ITGB6 to ensure target selectivity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay calibration. |
| False Positives in Cell Assays | Sequence-verified siRNA pool included for target knockdown and specificity validation. |
Live ITGB8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ITGB8 therapeutics is intensifying, with major players shifting focus from traditional pan-TGF-beta inhibitors to selective integrin alpha-v/beta-8 (αvβ8) blockers. By inhibiting ITGB8, therapeutics selectively block the activation of latent TGF-beta in the tumor microenvironment, avoiding the severe systemic toxicities associated with complete TGF-beta pathway blockade. As first-generation therapies reach the clinic, the next wave of R&D is targeting bispecific modalities and combinations with immune checkpoint inhibitors to overcome anti-PD-1 resistance in "cold" tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | GSK, Pfizer, Scholar Rock | Advanced Solid Tumors, NSCLC, Urothelial Carcinoma | Blockade Assay (Requires high-purity ITGAV/ITGB8 heterodimer and TGFB1 pathway reagents) |
| Bispecific Antibodies | Adagene, Novarock Biotherapeutics | CPI-Refractory Tumors | Dual-targeting validation (Requires both ITGB8 and PDCD1/PD-L1 high-affinity proteins) |
| Small Molecule Inhibitors | Morphic Therapeutic | Fibrotic Diseases, Oncology | Selectivity Screening (Requires a comprehensive panel of Integrin beta subfamilies) |